Peptidos en Inmunoterapia del Cancer
Categorías: Función Inmune, Sistema Inmune, Reparación y Recuperación
Los peptidos tumorales pueden educar al sistema inmune para reconocer y destruir celulas cancerosas.
Resumen Simplificado
Vacunas peptidicas, CAR-T peptidicos y checkpoint moduladores representan nuevas armas contra el cancer.
Antigenos tumorales peptidicos
Tumores expresan antigenos. Tipos. TAAs. Tumor-associated antigens. Overexpressed normal proteins. MUC1. HER2. CEA. WT1. TSAs. Tumor-specific antigens. Neoantigens. Mutations create new sequences. Patient-specific. Ideal targets. Oncofetal. Expressed in tumors and fetus. Normally silent in adults. Presentation. MHC molecules. Peptide fragments. 8-10 AA for MHC I. 13-25 AA for MHC II. CD8 T cells recognize MHC I. CD4 T cells recognize MHC II. Identificacion. Mass spectrometry. Exome sequencing. Bioinformatics prediction. Validacion immunological. Tumor antigens are targets. For immune attack. Peptidos are the currency of immune recognition.
Vacunas peptidicas contra cancer
Vacunas peptidicas entrenan inmunidad. Estructura. Tumor peptide. Adyuvante. Delivery system. Tipos. Single peptide. Specific antigen. Multi-peptide cocktail. Multiple targets. Personalized. Patient neoantigens. Adyuvantes. Incomplete Freund. CpG oligos. Poly-ICLC. GM-CSF. Delivery systems. Liposomes. Nanoparticles. Dendritic cell loading. Clinical experience. Limited success historically. Recent advances. Neoantigen vaccines. Melanoma. Glioblastoma. Personalized approaches. Better outcomes. FDA approved. Not yet. But pipeline active. Sipuleucel-T. Not peptide. Cell-based. Approved prostate cancer. Peptide vaccines. Safe. Specific. But weak immunity. Need combination. With checkpoint inhibitors. With other immunotherapies. Vaccine field revitalized. Neoantigen focus. Personalization key.
Checkpoints inmunologicos y moduladores
Checkpoints frenan inmunidad. PD-1/PD-L1. Principal target. Antibodies approved. Pembrolizumab. Nivolumab. Atezolizumab. Not peptides. But pathway validated. CTLA-4. Ipilimumab. First checkpoint inhibitor. LAG-3. Relatlimab. Recently approved. TIM-3. TIGIT. In development. Peptidos approach. PD-1/PD-L1 peptides. Competitive inhibitors. Smaller than antibodies. Potential advantages. Tissue penetration. Manufacturing cost. Oral potential theoretical. Preclinical success. Clinical limited. Peptide stability challenge. Bispecific peptides. Block two checkpoints. Novel formats. Avidity effect. Checkpoint inhibitors revolutionized oncology. Peptides could expand access. Lower cost alternatives needed.
CAR-T y peptidos targeting
CAR-T cells are engineered. Chimeric antigen receptor. T cells modified. Express synthetic receptor. Target tumor antigen. CD19 CAR-Ts approved. B cell malignancies. BCMA CAR-Ts. Multiple myeloma. Limitation. Solid tumors difficult. Target selection critical. Peptide-based targeting. Peptide-centric CARs. Recognize peptide-MHC complex. Any tumor antigen possible. If presented by MHC. TCR-like CARs. Similar concept. Universal CAR-Ts. Peptide-based adaptors. FITC-binders. Biotin-binders. Adaptor molecules with targeting peptide. Flexible system. One CAR. Multiple adaptors. Different tumors. Peptide adaptors. Control specificity. Dosable. Reversible. Safety advantages. CAR-T is established. Peptide targeting expands possibilities. Solid tumors potentially addressable.
Peptidos bispecificos y redirectores
Bispecifics conectan celulas. Format. Two binding domains. One for tumor. One for immune cell. Redirects immune cell to tumor. BiTEs. Bispecific T cell engagers. Blinatumomab. CD19 x CD3. Approved ALL. Peptidos bispecificos. Smaller format. Peptide-antibody fusions. Two peptide domains. One tumor targeting. One immune engaging. Advantages. Better tissue penetration. Manufacturing simpler. Tandem peptides. Linked sequences. Multi-valent. Enhanced avidity. Tribodies. Three specificities. More complex. In development. Targeting. Tumor antigen peptide. CD3 peptide for T cells. CD16 peptide for NK cells. Multiple immune effectors possible. Bispecific peptides. Emerging field. Proof of concept in preclinical. Clinical translation beginning.
Combinaciones y futuro
Future is combination. Single agents insufficient. Peptide vaccine + checkpoint. Prime then release brake. Synergy demonstrated. CAR-T + peptide vaccine. Expand T cells in vivo. Persistence improved. Peptido + chemotherapy. Immunogenic cell death. Antigen release. Better vaccine response. Peptido + radiation. Similar concept. Abscopal effect enhanced. Personalized approaches. Neoantigen identification. Rapid manufacturing. Individual vaccines. Off-the-shelf peptides. Shared tumor antigens. Broader applicability. Manufacturing at scale. Cost reduction needed. Global access. Biomarkers. Predict response. Select patients. Optimize combinations. Monitoring. Immune response assays. Circulating tumor DNA. Early detection of relapse. Peptide immunotherapy is expanding. Multiple modalities. Combination strategies. Personalization advancing. Clinical impact growing.
Hallazgos Clave
- Los antigenos tumorales incluyen TAAs (sobreexpresados) y neoantigenos (mutaciones especificas)
- Las vacunas peptidicas neoantigenicas personalizadas muestran resultados prometedores
- Los peptidos pueden bloquear checkpoints como PD-1/PD-L1 con ventajas potenciales de costo
- Los CAR-Ts con adaptadores peptidicos permiten targeting flexible de tumores solidos
- Los bispecificos peptidicos redirigen celulas inmunes hacia tumores
- La combinacion de vacunas con checkpoints o CAR-T es el futuro
Más artículos en Función Inmune
Más artículos en Sistema Inmune
Artículos relacionados
Preguntas frecuentes
- Que son los neoantigenos y por que son importantes?
- Neoantigenos son peptidos derivados de mutaciones especificas del tumor, no presentes en tejido normal. Son altamente especificos del tumor, generan respuesta inmune potente, y no causan autoinmunidad. Las vacunas neoantigenicas personalizadas son la frontera actual de inmunoterapia peptidica.
- Como funcionan los CAR-T con adaptadores peptidicos?
- CAR-Ts universales expresan receptor para un tag (ej. FITC). Un adaptador peptidico tiene el tag por un lado y un targeting peptide por otro (ej. anti-tumor). El adaptador conecta el CAR-T al tumor. Cambiar el adaptador cambia el target sin modificar el CAR-T.
- Por que los peptidos son atractivos para bloquear checkpoints?
- Los peptidos son mas pequenos que anticuerpos (mejor penetracion tisular), mas faciles y baratos de manufacturar, y potencialmente orales. Pueden bloquear interacciones PD-1/PD-L1 competitivamente. El challenge es estabilidad y farmacocinetica.
- Que son los BiTEs y como se relacionan con peptidos?
- BiTEs (Bispecific T cell Engagers) son moleculas con dos brazos: uno une antigeno tumoral, otro une CD3 en celulas T. Esto redirige celulas T para matar tumor. Blinatumomab es BiTE aprobado. Versiones peptidicas de BiTEs buscan mejor penetracion y menor costo.